Leading into the ASH Annual Meeting, Dr. Kami Maddocks, professor in the Division of Hematology at The Ohio State University and medical director of infusion services at The James Comprehensive Cancer Center, provides an in-depth analysis of advancements in non-Hodgkin lymphoma care, with a focus on aggressive B-cell lymphoma. She explores the evolving roles of immunotherapies like CAR-T cells and bispecific antibodies in high-risk patient populations, discusses the impact of cell-of-origin testing on frontline treatment decisions, and evaluates the latest data guiding choices between R-CHOP, transplant, and CAR-T therapy after first relapse. Dr. Maddocks also highlights the promise of BTK inhibitors and maintenance approaches in transforming patient outcomes, offering insights into the future of lymphoma treatment.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
